Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 - PubMed (original) (raw)
Clinical Trial
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Joel Tepper et al. J Clin Oncol. 2008.
Abstract
Purpose: The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although primary radiation therapy with concurrent chemotherapy produces similar results. As both have curative potential, there has been great interest in the use of trimodality therapy. To this end, we compared survival, response, and patterns of failure of trimodality therapy to esophagectomy alone in patients with nonmetastatic esophageal cancer.
Patients and methods: Four hundred seventy-five eligible patients were planned for enrollment. Patients were randomly assigned to either esophagectomy with node dissection alone or cisplatin 100 mg/m(2) and fluorouracil 1,000 mg/m(2)/d for 4 days on weeks 1 and 5 concurrent with radiation therapy (50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection.
Results: Fifty-six patients were enrolled between October 1997 and March 2000, when the trial was closed due to poor accrual. Thirty patients were randomly assigned to trimodality therapy and 26 were assigned to surgery alone. Patient and tumor characteristics were similar between groups. Treatment was generally well tolerated. Median follow-up was 6 years. An intent-to-treat analysis showed a median survival of 4.48 v 1.79 years in favor of trimodality therapy (exact stratified log-rank, P = .002). Five-year survival was 39% (95% CI, 21% to 57%) v 16% (95% CI, 5% to 33%) in favor of trimodality therapy.
Conclusion: The results from this trial reflect a long-term survival advantage with the use of chemoradiotherapy followed by surgery in the treatment of esophageal cancer, and support trimodality therapy as a standard of care for patients with this disease.
Conflict of interest statement
Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest.
Figures
Fig 1
CONSORT diagram.
Fig 2
Kaplan-Meier estimates of overall survival (OS) by treatment arm measured from study entry until death from any cause. (*) NE, not estimable. †Asymptotic results for OS were comparable to those obtained using the exact method.
Fig 3
Kaplan-Meier estimates of progression-free survival (PFS) by treatment arm measured from study entry until documented progression of disease or death from any cause. (*) NE, not estimable. †Asymptotic results for PFS were comparable to those obtained using the exact method.
Comment in
- Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?
Pereira B, Gourgou-Bourgade S, Azria D, Ychou M. Pereira B, et al. J Clin Oncol. 2008 Nov 1;26(31):5133-4; author reply 5134. doi: 10.1200/JCO.2008.19.0322. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838699 No abstract available.
Similar articles
- Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, Xu W, Ringash J, Keshavjee S, Chen E, Haider M, Darling G. Knox JJ, et al. Cancer. 2010 Sep 1;116(17):4023-32. doi: 10.1002/cncr.25349. Cancer. 2010. PMID: 20533506 Clinical Trial. - Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Kleinberg L, et al. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34. doi: 10.1016/s0360-3016(02)04598-4. Int J Radiat Oncol Biol Phys. 2003. PMID: 12738305 Clinical Trial. - Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M, Cook N, Prewett S, Hindmarsh A, Qian W, Gilligan D. Hategan M, et al. Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27. Dis Esophagus. 2015. PMID: 24863560 Review. - Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Jin J, et al. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380576 - Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Bates BA, et al. J Clin Oncol. 1996 Jan;14(1):156-63. doi: 10.1200/JCO.1996.14.1.156. J Clin Oncol. 1996. PMID: 8558191 Review.
Cited by
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.
Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, Fraumeni JF Jr, Curtis RE. Morton LM, et al. Blood. 2013 Apr 11;121(15):2996-3004. doi: 10.1182/blood-2012-08-448068. Epub 2013 Feb 14. Blood. 2013. PMID: 23412096 Free PMC article. - Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer.
Xu Y, Liu J, Du X, Sun X, Zheng Y, Chen J, Li B, Liu W, Jiang H, Mao W. Xu Y, et al. Radiat Oncol. 2013 May 8;8:116. doi: 10.1186/1748-717X-8-116. Radiat Oncol. 2013. PMID: 23656920 Free PMC article. - Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.
Hosoda K, Yamashita K, Katada N, Watanabe M. Hosoda K, et al. Gen Thorac Cardiovasc Surg. 2015 Oct;63(10):549-56. doi: 10.1007/s11748-015-0575-2. Epub 2015 Aug 1. Gen Thorac Cardiovasc Surg. 2015. PMID: 26232357 Review. - Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus.
Ku GY, Ilson DH. Ku GY, et al. Gastrointest Cancer Res. 2012 May;5(3):85-92. Gastrointest Cancer Res. 2012. PMID: 22888388 Free PMC article. - Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Matsuda S, et al. Ann Thorac Cardiovasc Surg. 2016 Oct 20;22(5):275-283. doi: 10.5761/atcs.ra.16-00111. Epub 2016 Jul 6. Ann Thorac Cardiovasc Surg. 2016. PMID: 27384595 Free PMC article. Review.
References
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. - PubMed
- Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730. - PubMed
- Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol. 1996;14:156–163. - PubMed
- Forastiere A, Orringer M, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report. J Clin Oncol. 1993;11:1118–1123. - PubMed
- Kavanagh B, Anscher M, Leopold K, et al. Patterns of failure following combined modality therapy for esophageal cancer, 1984–1990. Int J Radiat Oncol Biol Phys. 1992;24:633–642. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials